A male infant with Xq22.2q22.3 duplication containing PLP1 and MID2.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
03 2020
Historique:
received: 20 05 2019
revised: 26 10 2019
accepted: 11 11 2019
pubmed: 18 1 2020
medline: 30 3 2021
entrez: 18 1 2020
Statut: ppublish

Résumé

The Xq22.2 q23 is a complex genomic region which includes the genes MID2 and PLP1 associated with FG syndrome 5 and Pelizaeus-Merzbacher disease, respectively. There is limited information regarding the clinical outcomes observed in patients with deletions within this region. We report on a male infant with intrauterine growth retardation (IUGR) who developed head titubation and spasticity during his postnatal hospital course. Chromosome microarray revealed a 6.7 Mb interstitial duplication of Xq22.2q22.3. Fluorescence in situ hybridization showed that the patient's mother also possessed the identical duplication in the Xq22.3q22.3 region. Among the 34 OMIM genes in this interval, the duplication of the PLP1 (OMIM# 300401) and MID2 (OMIM# 300204) appears to be the most significant contributors to the patient's clinical features. Mutations and duplications of PLP1 are associated with X-linked recessive Pelizaeus-Merzbacher disease (PMD). A single case of a Xq22.3 duplication including the MID2 has been reported in boy with features of FG syndrome. However, our patient's clinical features are not consistent with the FG syndrome phenotype. Our patient's clinical features appear to be influenced by the PLP1 duplication but the clinical effect of other dosage sensitive genes influencing brain development cannot be ruled out.

Sections du résumé

BACKGROUND
The Xq22.2 q23 is a complex genomic region which includes the genes MID2 and PLP1 associated with FG syndrome 5 and Pelizaeus-Merzbacher disease, respectively. There is limited information regarding the clinical outcomes observed in patients with deletions within this region.
METHODS
We report on a male infant with intrauterine growth retardation (IUGR) who developed head titubation and spasticity during his postnatal hospital course.
RESULTS
Chromosome microarray revealed a 6.7 Mb interstitial duplication of Xq22.2q22.3. Fluorescence in situ hybridization showed that the patient's mother also possessed the identical duplication in the Xq22.3q22.3 region. Among the 34 OMIM genes in this interval, the duplication of the PLP1 (OMIM# 300401) and MID2 (OMIM# 300204) appears to be the most significant contributors to the patient's clinical features. Mutations and duplications of PLP1 are associated with X-linked recessive Pelizaeus-Merzbacher disease (PMD). A single case of a Xq22.3 duplication including the MID2 has been reported in boy with features of FG syndrome. However, our patient's clinical features are not consistent with the FG syndrome phenotype.
CONCLUSION
Our patient's clinical features appear to be influenced by the PLP1 duplication but the clinical effect of other dosage sensitive genes influencing brain development cannot be ruled out.

Identifiants

pubmed: 31951325
doi: 10.1002/mgg3.1078
pmc: PMC7057127
doi:

Substances chimiques

MID2 protein, human 0
Microtubule-Associated Proteins 0
Myelin Proteolipid Protein 0
PLP1 protein, human 0
Transcription Factors 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1078

Informations de copyright

© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Am J Hum Genet. 2009 Feb;84(2):162-77
pubmed: 19200522
Nat Med. 1996 Dec;2(12):1322-8
pubmed: 8946830
J Hum Genet. 2000;45(5):318-22
pubmed: 11043518
Nat Genet. 2001 Apr;27(4):422-6
pubmed: 11279525
Immunity. 2003 Apr;18(4):535-47
pubmed: 12705856
Br J Haematol. 2007 Aug;138(4):479-86
pubmed: 17608765
J Biol Chem. 2000 Jul 7;275(27):20533-9
pubmed: 10801798
J Med Genet. 2017 Apr;54(4):269-277
pubmed: 27811305
Proc Natl Acad Sci U S A. 1986 Dec;83(24):9807-11
pubmed: 3467339
Hum Mutat. 2014 Jan;35(1):41-4
pubmed: 24115387
Am J Hum Genet. 2017 Jan 5;100(1):160-168
pubmed: 28041644
J Biol Chem. 1998 Apr 24;273(17):10726-32
pubmed: 9553137
Eur J Hum Genet. 2014 Feb;22(2):208-15
pubmed: 23714752
Mol Genet Genomic Med. 2015 Dec 12;4(1):95-105
pubmed: 26788540
Am J Med Genet A. 2005 Dec 15;139(3):221-6
pubmed: 16283679
Cancer Immun. 2006 Jan 12;6:2
pubmed: 16405301
Genomics. 2004 Oct;84(4):745-56
pubmed: 15475252
Hum Mutat. 1997;9(6):477-99
pubmed: 9195222
J Biol Chem. 2002 Jun 14;277(24):21361-70
pubmed: 11934881
Genomics. 2000 Oct 15;69(2):252-62
pubmed: 11031108
Nat Genet. 1998 Nov;20(3):309-11
pubmed: 9806555
Hum Mol Genet. 2017 May 15;26(10):1927-1941
pubmed: 28334874
Mol Cell Biol. 1999 Feb;19(2):1479-85
pubmed: 9891081
J Med Genet. 2002 May;39(5):359-65
pubmed: 12011158
Am J Hum Genet. 2005 Dec;77(6):966-87
pubmed: 16380909
Hum Mol Genet. 1999 Aug;8(8):1397-407
pubmed: 10400986
Mol Genet Genomic Med. 2020 Mar;8(3):e1078
pubmed: 31951325
Z Kinderheilkd. 1974 Apr 8;117(1):1-18
pubmed: 4365204
Mol Aspects Med. 2013 Apr-Jun;34(2-3):465-84
pubmed: 23266187
Mol Cell Biol. 2000 Dec;20(23):8996-9008
pubmed: 11073998
J Biol Chem. 2003 Feb 7;278(6):3671-8
pubmed: 12446702
Clin Genet. 2008 Mar;73(3):279-87
pubmed: 18190592
J Clin Endocrinol Metab. 2000 Nov;85(11):3996-9
pubmed: 11095421
Am J Med Genet. 2002 Sep 15;112(1):6-11
pubmed: 12239712
DNA Res. 2001 Apr 27;8(2):85-95
pubmed: 11347906
Nucleic Acids Res. 1990 Jan 11;18(1):193
pubmed: 2155397
Am J Hum Genet. 2019 Feb 7;104(2):348-355
pubmed: 30661770
Genomics. 1989 Apr;4(3):367-75
pubmed: 2541066
Dev Cell. 2005 Dec;9(6):735-44
pubmed: 16326386
J Biol Chem. 1993 Dec 15;268(35):26476-81
pubmed: 8253776
Clin Genet. 2012 Jun;81(6):532-41
pubmed: 21623770
Nat Genet. 2007 Apr;39(4):451-3
pubmed: 17334363
Blood. 2001 Aug 1;98(3):743-53
pubmed: 11468175
Am J Med Genet A. 2007 Aug 15;143A(16):1876-9
pubmed: 17632775
Genomics. 1996 Feb 1;31(3):367-72
pubmed: 8838319
Genomics. 2001 May 15;74(1):105-8
pubmed: 11374906

Auteurs

Swati R Chanchani (SR)

Department of Pediatrics St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, USA.

Hongyan Xie (H)

Tricore Reference Laboratory, Albuquerque, NM, USA.

Gurbax Sekhon (G)

Integrated Genetics, NM, Santa Fe, USA.

Ana M Melikishvili (AM)

A. I. Dupont Hospital, Wilmington, DE, USA.

Sue Moyer Harasink (S)

Department of Pediatrics St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, USA.

Harpreet Pall (H)

Department of Pediatrics St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, USA.

Philip F Giampietro (PF)

Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH